La Jolla Pharmaceutical Co. (NASDAQ:LJPC) shares were down 1.7% on Monday . The company traded as low as $16.49 and last traded at $16.56, with a volume of 104,355 shares trading hands. The stock had previously closed at $16.85.

A number of research analysts recently weighed in on LJPC shares. Lake Street Capital started coverage on shares of La Jolla Pharmaceutical in a report on Tuesday, May 24th. They issued a “buy” rating and a $25.00 price objective for the company. SunTrust Banks Inc. started coverage on shares of La Jolla Pharmaceutical in a report on Wednesday, June 22nd. They issued a “buy” rating and a $30.00 price objective for the company. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, Jefferies Group restated a “buy” rating on shares of La Jolla Pharmaceutical in a report on Wednesday, June 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $39.50.

The stock’s market capitalization is $302.29 million. The stock has a 50-day moving average price of $16.67 and a 200 day moving average price of $18.10.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings data on Friday, May 6th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.22. Analysts forecast that La Jolla Pharmaceutical Co. will post ($3.99) EPS for the current fiscal year.

An institutional investor recently raised its position in La Jolla Pharmaceutical stock. P.A.W. Capital Corp increased its position in shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical accounts for about 1.5% of P.A.W. Capital Corp’s investment portfolio, making the stock its 28th largest position. P.A.W. Capital Corp owned approximately 0.28% of La Jolla Pharmaceutical worth $1,361,000 as of its most recent filing with the SEC.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.